Classification of PRSS1 variants responsible for chronic pancreatitis: An expert perspective from the Franco-Chinese GREPAN Study Group

Background: PRSS1 was the first reported chronic pancreatitis (CP) gene. The existence of both gain-offunction (GoF) and gain-of-proteotoxicity (GoP) pathological PRSS1 variants, together with the fact that PRSS1 variants have been identified in CP subtypes spanning the range from monogenic to multifactorial, has made the classification of PRSS1 variants very challenging. Methods: All currently reported PRSS1 variants (derived primarily from two databases) were manually reviewed with respect to their clinical genetics, functional analysis and population allele frequency. They were classified by variant type and pathological mechanism within the framework of our recently proposed ACMG/AMP guidelines-based seven-category system. Results: The total number of distinct germline PRSS1 variants included for analysis was 100, comprising 3 copy number variants (CNVs), 12 50 and 30 variants, 19 intronic variants, 5 nonsense variants, 1 frameshift deletion variant, 6 synonymous variants, 1 in-frame duplication, 3 gene conversions and 50 missense variants. Based upon a combination of clinical genetic and functional analysis, population data and in silico analysis, we classified 26 variants (all 3 CNVs, the in-frame duplication, all 3 gene conversions and 19 missense) as pathogenic, 3 variants (missense) as likely pathogenic, 5 variants (four missense and one promoter) as predisposing, 13 variants (all missense) as unknown significance, 2 variants (missense) as likely benign, and all remaining 51 variants as benign. Conclusions: We describe an expert classification of the 100 PRSS1 variants reported to date. The results have immediate implications for reclassifying many ClinVar-registered PRSS1 variants as well as providing optimal guidelines/standards for reporting PRSS1 variants. 0 2023 IAP and EPC. Published by Elsevier B.V. All rights reserved.

Automated summary

The researchers reviewed and classified 100 PRSS1 variants, proposing a new classification system based on clinical genetics, functional analysis, population data, and in silico analysis. They categorized 26 variants as pathogenic, 3 variants as likely pathogenic, 5 variants as predisposing, 13 variants as of unknown significance, 2 variants as likely benign, and the remaining 51 variants as benign.